The Technical Analyst
Flexion Therapeutics Inc [FLXN]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Flexion Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $9.12
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-02-09 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.80 - 9.44 ( +/- 3.52%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-19 | Newtyn Management, Llc | Sell | 5 900 000 | Common Stock, par value $0.001 per share |
| 2021-11-18 | Newtyn Management, Llc | Buy | 0 | Common Stock, par value $0.001 per share |
| 2021-11-19 | Stejbach Mark | Sell | 12 631 | Common Stock |
| 2021-11-19 | Stejbach Mark | Sell | 25 000 | Stock option (right to buy) |
| 2021-11-19 | Stejbach Mark | Sell | 12 500 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 99 transactions |
| Buy: 271 750 | Sell: 9 779 666 |
Forecast:
01:40 - $8.66
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.12 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 2.17 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FLXN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FLXN
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest Press Releases
2021-11-01 21:25:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Dwsn, Pae, Xlrn, And Flxn Shareholders About Its Ongoing Investigations
New york, nov. 1, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com dawson geophysical company (nasdaq: dwsn) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dawson geophysical company (nasdaq: dwsn) in connection with the proposed acquisition of dwsn by a subsidiary of wilks brothers, llc.
2021-10-28 14:25:00 - Press Release
Shareholder Investigation: Halper Sadeh Llp Investigates Ftsi, Umpq, Flxn, Adms; Shareholders Are Encouraged To Contact The Firm
New york, oct. 28, 2021 /prnewswire/ -- halper sadeh llp, a global investor rights law firm, announces it is investigating the following companies: fts international, inc. (nyse: ftsi) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to profrac holdings, llc for $26.52 per share in cash. if you are an fts international shareholder, click here to learn more about your rights and options.
2021-10-26 21:48:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Adms, Flxn, Azpn, And Ebmt Shareholders About Its Ongoing Investigations
New york, oct. 26, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com adamas pharmaceuticals, inc. (nasdaq: adms) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of adamas pharmaceuticals, inc. (nasdaq: adms) in connection with the proposed acquisition of the company by supernus pharmaceuticals, inc. under the terms of the agreement, adms shareholders will receive $8...
2021-10-11 23:41:00 - Press Release
Shareholder Alert: Weisslaw Llp Investigates Flexion Therapeutics, Inc.
New york, oct. 11, 2021 /prnewswire/ -- weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of flexion therapeutics, inc. ("flexion" or the "company") (nasdaq: flxn) in connection with the proposed acquisition of the company by pacira biosciences, inc. ("pacira") (nasdaq: pcrx). under the terms of the merger agreement, pacira will commence a tender offer to acquire all outstanding shares of flexion for a purchase price of $8.50 per share in cash, plus one non-tradeable contingent value right ("cvr").
2021-10-11 16:26:00 - Press Release
Alert: Rowley Law Pllc Is Investigating Proposed Acquisition Of Flexion Therapeutics, Inc.
New york, oct. 11, 2021 /prnewswire/ -- rowley law pllc is investigating potential securities law violations by flexion therapeutics, inc. (nasdaq: flxn) and its board of directors concerning the proposed acquisition of the company by pacira biosciences, inc. (nasdaq: pcrx). stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of flexion therapeutics stock that they hold.
Latest News
2021-10-25 15:09:05 - Zacks Investment Research
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
2021-10-23 09:24:01 - Seeking Alpha
Flexion Therapeutics: Bullish On The Buyout
Flexion Therapeutics recently announced that they have agreed to be acquired by Pacira BioSciences for $8.50 a share bid with the potential for an extra $8 from CVR. I provide a brief background on Pacira BioSciences and some of the details of the deal.
2021-10-11 16:26:00 - PRNewsWire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold.
2021-10-11 15:09:00 - Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.
New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Flexion Therapeutics, Inc. (NASDAQ: FLXN) ("Flexion Therapeutics" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:
2021-10-11 13:50:00 - PRNewsWire
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with Pacira. Click here to learn how to join the action: https://www.ademilaw.com/case/flexion-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
2021-10-11 12:00:00 - Business Wire
Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8.00 per share in cash is fair to Flexion shareholders. Halper Sadeh encourages Flexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060
2021-10-11 08:32:26 - Pulse2
FLXN Stock: Why It Substantially Increased Today
The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened.
2021-10-11 07:13:46 - Market Watch
Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences
Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.
2021-10-11 07:00:00 - GlobeNewsWire
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
2021-10-01 16:30:00 - GlobeNewsWire
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).